Dent Neurologic Institute   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Amherst NY United States (1963)

Organization Overview

First Clinical Trial
2010
NCT00893594
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dizziness (Phase 3)

Glioblastoma (Phase 2)

Meniere Disease (Phase 3)

Migraine Disorders (Phase 2)

Neoplasm Metastasis (Phase 2)

Vertigo (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 7